LEADER 03039nam  22005175  450 
001 9910337486703321
005 20200702083944.0
010   $a3-030-11392-2
024 7 $a10.1007/978-3-030-11392-6
035   $a(CKB)4100000008048015
035   $a(MiAaPQ)EBC5771277
035   $a(DE-He213)978-3-030-11392-6
035   $a(PPN)235669156
035   $a(EXLCZ)994100000008048015
100   $a20190424d2019      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aChronic Lymphocytic Leukemia /$fedited by Michael Hallek, Barbara Eichhorst, Daniel Catovsky
205   $a1st ed. 2019.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019.
215   $a1 online resource (171 pages)
225 1 $aHematologic Malignancies,$x2197-9766
311   $a3-030-11391-4 
327   $aPathophysiolgoy -- Diagnostics -- Clinical Presentation -- Prognostic Markers -- Treatment -- Follow-up and Complications -- Related Entities.
330   $aThis book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapy of T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed. .
410  0$aHematologic Malignancies,$x2197-9766
606   $aHematology
606   $aOncology
606   $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
615  0$aHematology.
615  0$aOncology.
615 14$aHematology.
615 24$aOncology.
676   $a616.99419
676   $a616.99419
702   $aHallek$b Michael$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aEichhorst$b Barbara$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aCatovsky$b Daniel$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910337486703321
996   $aChronic Lymphocytic Leukemia$91736792
997   $aUNINA